APA (7th ed.) Citation

AP, K., MHJ, v. O., Y, v. N., L, v. d. S., J, D., WFM, P., . . . MD, L. (2019). Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. Haematologica, 104(1), 147. https://doi.org/10.3324/haematol.2018.193854

Chicago Style (17th ed.) Citation

AP, Kater, et al. "Feasibility and Efficacy of Addition of Individualized-dose Lenalidomide to Chlorambucil and Rituximab as First-line Treatment in Elderly and FCR-unfit Patients with Advanced Chronic Lymphocytic Leukemia." Haematologica 104, no. 1 (2019): 147. https://doi.org/10.3324/haematol.2018.193854.

MLA (9th ed.) Citation

AP, Kater, et al. "Feasibility and Efficacy of Addition of Individualized-dose Lenalidomide to Chlorambucil and Rituximab as First-line Treatment in Elderly and FCR-unfit Patients with Advanced Chronic Lymphocytic Leukemia." Haematologica, vol. 104, no. 1, 2019, p. 147, https://doi.org/10.3324/haematol.2018.193854.